Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens strain:pancreatic adenocarcinoma epithelial cell line | breed:PL45

ABSTRACT: Homo sapiens strain:pancreatic adenocarcinoma epithelial cell line | breed:PL45 Genome sequencing and assembly

PROVIDER: PRJNA1173801 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31023622_1.fastq.gz	Fastqsanger.gz
	SRR31023622_2.fastq.gz	Fastqsanger.gz
	SRR31023623_1.fastq.gz	Fastqsanger.gz
	SRR31023623_2.fastq.gz	Fastqsanger.gz
	SRR31023624_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Expression data from TGF-beta treated Panc-1 pancreatic adenocarcinoma cell line

Project description:TGF-beta treatment of Panc-1 pancreatic adenocarcinoma cell line on Affymetrix HG_U133_plus_2 arrays; triplicate experiments. The goal of the experiment is to profile temporal gene expression changes during TGF-beta-induced epithelial-mesenchymal transition (EMT). During EMT cancer cells lose their epithelial specifc proteins and gain mesenchymal proteins to acquire migratory and invasive phenotype essential for metastasis. Human Panc-1 pancreatic adenocarcinoma cell line was treated with 5 ng/mL TGF-beta for 48 h to induce EMT. The experiment was repeated 3 times. Samples were assayed using Affymetrix HG_U133_plus_2 arrays with 54675 probe-sets, using standard techniques. Human Panc-1 pancreatic adenocarcinoma cell line was treated with 5 ng/mL TGF-beta for 48 h. The experiment was repeated 3 times. Samples were assayed using Affymetrix HG_U133_plus_2 arrays with 54675 probe-sets, using standard techniques.

2010-09-03 | E-GEOD-23952 | biostudies-arrayexpress

Expression data from TGF-beta treated Panc-1 pancreatic adenocarcinoma cell line

2010-09-03 | GSE23952 | GEO

LLGL1 depletion effect on pancreatic ductal adenocarcinoma cell line CAPAN2

Project description:Identification of gene regulated by LLGL1 in pancreatic ductal adenocarcinoma cell line CAPAN2

2015-01-06 | GSE64681 | GEO

Pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma

| PRJNA432344 | ENA

SAMD1 suppresses epithelial-mesenchymal transition pathways in pancreatic ductal adenocarcinoma

Project description:SAMD1 suppresses epithelial-mesenchymal transition pathways in pancreatic ductal adenocarcinoma

| PRJNA999235 | ENA

LINE-1 ORF1p immune evasion mechanisms in pancreatic ductal adenocarcinoma

Project description:LINE-1 ORF1p immune evasion mechanisms in pancreatic ductal adenocarcinoma

| PRJNA1211127 | ENA

Asymmetric dimethylarginine proteome of pancreatic ductal adenocarcinoma.

Project description:Protein arginine methylation has been established an essential protein modification regulating cancer initiation and progression, but its implications in PDAC (Pancreatic ductal adenocarcinoma) still remains poorly elucidated. In this study, we characterized ADMA (asymmetric dimethylarginine)-bearing peptides in human pancreatic ductal epithelium cell line HPDE6c7 and PDAC cell line PANC-1 by a label-free quantitative proteomics combined with affinity purification.

2020-02-18 | PXD017577 |

Genome profiling of pancreatic adenocarcinoma

Project description:Pancreatic adenocarcinoma is one of the most aggressive human cancers and displays many different chromosomal abnormalities and mutations. By using 244K high-resolution array-comparative genomic hybridization (aCGH) we studied the genome alterations of 39 fine-needle aspirations from pancreatic adenocarcinoma and 9 human adenocarcinoma pancreatic cell lines.

2011-12-31 | E-MTAB-570 | biostudies-arrayexpress

In vitro microRNA screening in human pancreatic adenocarcinoma

Project description:No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses chemoresistant PDAC for its specific miR expression pattern. Gemcitabine-resistant variants of PANC-1, a mutant p53 human pancreatic adenocarcinoma cell line, were established. MicroRNA screening was investigated by microarray.

2015-11-03 | GSE74562 | GEO

Induced Pluripotent Stem Cells From Pancreatic Ductal Adenocarcinoma Can Recapitulate Early Developmental Stages of Cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of any human malignancy and there are few human cellular models of disease progression. When human PDAC cells are injected into immunodeficient animals, they create tumors of the late stage from which they were derived. We hypothesized that if human pancreatic cancer cells were converted to pluripotency and then allowed to differentiate back into pancreas, the developmental progression would recapitulate early stages of the cancer. To that end, we have generated isogenic matched sets of induced pluripotent stem (iPS) cell-like lines from epithelial cells of human pancreatic tumors and from histologically normal epithelial cells at the resected pancreatic margins. Notably, when injected into immunodeficient mice, at low or high passages, a human pancreatic cancer iPS-like line, but not the corresponding margin iPS-like line, slowly generates intra-epithelial neoplasia (PanIN) ductal structures that typically reflect the early stages of human pancreatic cancer. The PanIN-like ducts can be isolated and cultured. They secrete protein products reflective of PanINs and provide new insights into underlying regulatory networks. An additional iPS-like line from histologically normal cells at a pancreatic resection margin, but containing a mutation that predisposes to PDAC, does not generate PanIN ductal structures. These studies demonstrate that iPS technology can be exploited to recapitulate early progression events of a human epithelial cancer. Study includes a single experiment (#10): a tumor-adjacent pancreatic tissue control (10N); tumor tissue (10C); IPS-transformed tissue control (10N12); and IPS-transformed tumor tissue (10C22).

2013-06-20 | E-GEOD-47985 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data